The national procurement of proprietary Chinese medicines is getting closer and closer, and another major news has just come out

On February 11, the State Council Information Office held a regular policy briefing and revealed that: in the next step, the National Medical Insurance Bureau will normalize and institutionalize the centralized procurement of drugs and high-value medical consumables.
The three major sectors of Chinese patent medicine and biological medicine are carried out, and high-value medical consumables focus on orthopedic consumables, drug balloons, dental implants and other varieties
.
By the end of 2022, the total number of national and provincial-level centralized procurement of drugs will reach more than 350 in each province, and the number of high-value medical consumables will reach more than 5 varieties
.
In fact, the centralized procurement of Chinese patent medicines has affected the sensitive nerves of the hundreds of billions of Chinese patent medicine market very early
.
In July 2020, the relevant departments of the National Medical Insurance Bureau held a symposium on the centralized procurement of biological products and proprietary Chinese medicines, to study and improve the procurement policies in related fields, and to release the signal of centralized procurement or centralized procurement of proprietary Chinese medicines; in September of the same year, the National Medical Insurance Administration A reply stated that it will further study and explore the centralized procurement of unreviewed drugs and drugs for which there is no consistent evaluation standard, such as biological products and proprietary Chinese medicines; in January 2021, on promoting centralized drug distribution.
In the opinion on the normalization and institutionalization of volume procurement work, it is mentioned that "exploring the combination of different generic drugs with similar indications or functions and main functions to carry out centralized volume procurement", etc.
, these have released the variety of Chinese patent medicines that will be included in the centralized procurement sooner or later.
's signal
.
At present, although no proprietary Chinese medicines have been included in large-scale centralized procurement, many places have already taken action
.
For example, Qinghai, Zhejiang Jinhua, Henan Puyang and other places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with large demand and high value in recent years, and achieved certain results
.
At the end of 2021, the inter-provincial alliance of 19 provinces led by Hubei will carry out the centralized procurement of Chinese patent medicines
.
Recently, Hubei led the 19-province alliance to open bids for the centralized procurement of proprietary Chinese medicines.
The results of this centralized procurement show that a total of 97 companies and 111 products were selected, and the selected prices dropped by an average of 42.
27%, of which there were products that fell by more than 82%
.
It is understood that the selected products of the Chinese Patent Medicine Alliance have complete dosage forms and specifications, which can effectively meet the needs of clinical and normalized epidemic prevention and control drugs
.
According to the forecast, this centralized procurement is expected to save patients more than 2.
6 billion yuan in drug costs every year. .
In addition, it is generally believed in the industry that the price reduction effect of the centralized procurement of the Chinese patent medicine alliance may radiate to the whole country
.
Another person said that this year, on the basis that some provinces have organized the procurement of Chinese patent medicine alliances last year, the scope will be further expanded in an orderly manner
.
There are certain difficulties in the national procurement of Chinese patent medicines, mainly because Chinese patent medicines are not like chemical drugs, they are special, their quality is difficult to evaluate, and there are many exclusive products, so it is difficult to carry out centralized procurement
.
However, judging from the signals released by the National Medical Insurance Bureau in recent years, the national procurement of proprietary Chinese medicines is a sure thing, but it will take time to advance
.
Now, the National Medical Insurance Bureau has clearly revealed that the centralized procurement of medicines will be carried out in three major sectors including Chinese patent medicines, which also means that the national procurement of Chinese patent medicines is getting closer and closer, and relevant companies may prepare for it in advance
.
At present, Chinese patent medicine-related companies have a more positive attitude towards centralized procurement
.
For example, Yiling Pharmaceutical recently replied to investors on the interactive platform that Lianhua Qingwen products had been included in the centralized procurement of Chinese patent medicines by six provincial alliances including Guangdong, and the centralized procurement is still in progress
.
The company will seriously and actively participate in this centralized procurement.
At the same time, it will also intensify efforts to control costs and increase efficiency in the future, and strive to achieve a relatively stable net profit rate
.